Although most patients with advanced EGFR-mutated NSCLC initially respond to treatment with third-generation EGFR-TKIs, real-world survival estimates indicated that only 19% of patients were alive after 5 years (Bazhenova et al., 2021). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.